Evidence map›Paper›PMID 33996584›Full record

ArticleFrontiers in oncology2021

Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Children's Oncology Group (ANZCHOG) Study.

Anne L Ryan, Charlotte Burns, Aditya K Gupta, Ruvishani Samarasekera, David S Ziegler, Maria L Kirby, Frank Alvaro, Peter Downie, Stephen J Laughton, Siobhan Cross and 5 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anne L RyanDepartment of Haematology, Oncology and Bone Marrow Transplant, Perth Children's Hospital, Perth, WA, Australia.
Charlotte BurnsChildren's Cancer Centre, The Royal Children's Hospital, Melbourne, VIC, Australia.
Aditya K GuptaCancer Centre for Children, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Ruvishani SamarasekeraKids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.
David S ZieglerKids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.
Maria L KirbyDepartment of Haematology/Oncology, Women's and Children's Hospital, Adelaide, SA, Australia.
Frank AlvaroDepartment of Haematology/Oncology, John Hunter Children's Hospital, Newcastle, NSW, Australia.
Peter DownieChildren's Cancer Centre, The Royal Children's Hospital, Melbourne, VIC, Australia.
Stephen J LaughtonStarship Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.
Siobhan CrossChildren's Haematology/Oncology Centre, Christchurch Hospital, Christchurch, New Zealand.
Timothy HassallDepartment of Haematology/Oncology, Queensland Children's Hospital, Brisbane, QLD, Australia.
Geoff B McCowageCancer Centre for Children, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Jordan R HansfordChildren's Cancer Centre, The Royal Children's Hospital, Melbourne, VIC, Australia.
Rishi S KotechaDepartment of Haematology, Oncology and Bone Marrow Transplant, Perth Children's Hospital, Perth, WA, Australia.
Nicholas G GottardoDepartment of Haematology, Oncology and Bone Marrow Transplant, Perth Children's Hospital, Perth, WA, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesUnlike adults, malignant melanoma in children and adolescents is rare. In adult melanoma, significant progress in understanding tumor biology and new treatments, including targeted therapies and immunotherapy have markedly improved overall survival. In sharp contrast, there is a paucity of data on the biology and clinical behavior of pediatric melanoma. We report a national case series of all pediatric and adolescent malignant melanoma presenting to ANZCHOG Childhood Cancer Centers in Australia and New Zealand.

methodsA retrospective, descriptive, multi-center study was undertaken to identify patients less than 18 years of age treated for cutaneous malignant melanoma over a twenty-year period (1994 to 2014). Data on clinical characteristics, histopathology, and extent of disease, treatment and follow-up are described.

resultsA total of 37 cases of malignant melanoma were identified from all of the Australasian tertiary Childhood Cancer Centers. The median age was 10 years (range 1 month - 17 years). Clinically, the most common type of lesion was pigmented, occurring in sixteen (57%) patients, whilst amelanotic was seen in 7 patients (25%). In 11 (27.9%) the Breslow thickness was greater than 4mm. A total of 11 (29.7%) patients relapsed and 90% of these died of disease. Five-year event free survival (EFS) and overall survival were 63.2 (95% CI: 40.6 - 79.1) and 67.7% (95% CI: 45.1 - 82.6) respectively.

conclusionOur data confirms that melanoma is a rare presentation of cancer to tertiary Australasian Childhood Cancer Centers with only 37 cases identified over two decades. Notably, melanoma managed in Childhood Cancer Centers is frequently at an advanced stage, with a high percentage of patients relapsing and the majority of these patients who relapsed died of disease. This study confirms previous clinical and prognostic information to support the early multidisciplinary management in Childhood Cancer Centers, in conjunction with expert adult melanoma centers, of this rare and challenging patient group.

Indexed as

childhoodcutaneous melanomadermatologyoutcomerare tumors

Identifiers

PMID33996584
PMCPMC8117414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.